Receive a study payment of £948 for your time
We are looking for Caucasian men and women with type 2 diabetes aged 18 to 65 years to test a potential (i.e. investigational) medicine to treat type 2 diabetes.
This trial will involve you staying with us for a few days (see below) at our private medical facility in London Bridge.
- The investigational medicine works by binding certain hormones which are produced after eating a meal, causing a decrease in blood sugar levels.
- The aim of this trial is to determine how safe and well tolerated the investigational medicine is when given to patients with type 2 diabetes.
- The trial will also assess how long the investigational medicine remains in the blood and how it affects the body.
- You will need to attend a screening appointment so we can determine if you are suitable to take part in the trial.
- If your screening visit results show you to are a good candidate for the trial you will be invited to take part and this will involve 1 in-house stay in our unit of 5 days / 4 nights.
- During your stay with us you will receive a single dose of the investigational medicine and we will conduct a number of assessments to check your safety and to help us understand how your body processes the drug.
- After your stay with us you will return for 1 follow-up visit 11 days after you are discharged from the unit.
*Only 1x screening appointment required
Who can take part?
- You are a Caucasian male or female.
- You have type 2 diabetes and are aged between 18 to 65 years. You have a Body Mass Index (BMI) within the range of 0 and 35.0 kg/m2.
- Your type 2 diabetes is treated with either:
- Diet and exercise alone, or
- A medication used to treat type 2 diabetes
- Metformin (brand names include Glucophage and Fortamet),
- A DPP-4 inhibitor/gliptin such as sitagliptin or linagliptin (brand names include Januvia and Trajenta),
- Pioglitazone (brand names include Actos and Glidipion),
- A sulphonylurea such as gliclazide or glibenclamide (brand names include Diamicron and Diabeta),
- An SGLT-2 inhibitor/gliflozin such as dapagliflozin or empagliflozin (brand names include Forxiga and Jardiance).
- You must be able to pause (washout) the medication you take (if you take any) to treat type 2 diabetes (above), to allow it to fully leave your system, prior to admission into the unit and for the duration of the trial.
- You must not have been treated with two blood-sugar lowering therapies, exenatide (Bydureon), dulaglutide (Trulicity), liraglutide (Victoza) or lixisenatide (Lixumia), in the 3 months prior to dosing.
- You must not have recently been in hospital due to low blood sugar (hypoglycaemia) or high blood sugar (hyperglycaemia) in the 3 months prior to dosing or Day -2.
- You must not have any complications of diabetes such as poor kidney function or eye disease, any other chronic illness or condition or psychiatric illness that could affect the results of the clinical trial.
- You must not consume tobacco in any form (e.g. smoking or chewing) or other nicotine-containing products (e.g. gum, patch, electronic cigarettes) 28 days prior to the planned admission (Day -2).
- You must not be pregnant or breastfeeding.
- Females: You must be willing to use appropriate contraception, starting from one complete menstrual cycle prior to the first day of dosing until the follow-up visit.
- Males: You must be willing to use appropriate contraception, starting from the first day of dosing until the follow-up visit.
A full list of acceptable contraceptive methods will be discussed in full by a member of the recruitment team and a trial doctor during screening.
In recognition of the time involved in taking part in this trial, you will receive £948 (£630 study payment and £318 bonus) on completion of the study provided you comply fully with all the trial requirements. This amount is based on the anticipated trial plan and will be adjusted pro-rata (i.e. same amount of money paid per unit of time), should we invite you to attend extra visits.
Contact our Volunteer Recruitment team
For more information call +44 (0) 20 7042 5800 or email:Register your interest in this clinical trial
You may be required to remain resident in the unit until resolution of any safety issues, after which you will be discharged from the unit.
The contents of this page have been approved by an ethics committee. Any response to this advertisement will be recorded. Your response will not place you under any obligation to participate in this trial.
Ref: C19040_Jun2020 (email_website_advert text)